NHS Under Pressure as Bristol Myers Squibb Demands Higher Prices for New Medicines

Bristol Myers Squibb BMS has issued a pointed demand for the NHS to fund a greater share of pharmaceutical innovation calling for the UK to pay what it describes as a fair contribution toward new drug development In a move that aligns with emerging White House rhetoric BMS stated it would price its new schizophrenia medication Cobenfy equally in the UK and US with a proposed annual price tag of 22500 dollars or approximately 16700 pounds for the NHS

This development followed American government calls led by President Donald Trump for pharmaceutical companies to halt what he labelled as subsidised drug provision in countries such as Britain US consumers he argued have long borne the cost of cheaper international drug pricing by paying inflated prices at home Trump has urged pharmaceutical giants to harmonise pricing structures globally with a deadline of late September a stance that BMS now echoes in its UK policy

BMS Chief Commercial Officer Adam Lenkowsky told the Financial Times that the UK needed to step up in its contribution to pharmaceutical research and development He expressed agreement with the Trump administration that other prosperous countries must support the cost of global medical innovation The figures are stark Britain currently spends 028 per cent of its GDP on innovative medicines compared with the US proportion of 078 per cent placing it low in the G7 league

The immediate pressure on the NHS is compounded by the fact that Cobenfy has yet to secure approval from the National Institute for Health and Care Excellence NICE which assesses the value and efficacy of treatments prior to NHS adoption BMS insists that its price matches the significant value the medicine brings to patients and society yet the onus is now on British authorities to determine whether this claim holds up under scrutiny

BMS UK chief Guy Oliver highlighted what he described as a challenging commercial environment for drug companies in Britain Drug manufacturers have voiced mounting concern about an NHS pricing scheme that allows government to claw back funding when medicine spending rises too quickly This has in turn pushed companies to delay or reconsider the launch of certain advanced treatments in the UK

The current debate raises profound questions over Britains future role in the global pharmaceutical ecosystem With pressure mounting on healthcare budgets and ongoing commentary from both the pharmaceutical sector and international leaders the outcome of this pricing standoff could shape NHS access to critical innovations for years to come